ATRX has been reported as a tumor suppressor that is frequently mutated in a variety of tumors, including adult lower-grade gliomas, pediatric glioblastoma multiforme, pediatric osteosarcoma, neuroblastoma, and pancreatic neuroendocrine tumors [13,14,19,21]. Here, ATRX is linked to central nervous system cancer.